Global Clinical Trial (CTMS) 麻豆原创 Research Report 2023

Publication ID:

PB504239288

Publication Date:

April 11, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial 鈥� their approval does not mean that the therapy is 'safe' or effective, only that the trial may be conducted.
Highlights
The global Clinical Trial (CTMS) market was valued at US$ 48890 million in 2022 and is anticipated to reach US$ 62370 million by 2029, witnessing a CAGR of 4.1% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The industry's leading producers are Parexel, PRA Health and LabCorp (Covance), which accounted for 4.94%, 7.25% and 11.81% of revenue in 2019, respectively. By region, North America has the highest share of income, at more than 39 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Clinical Trial (CTMS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Trial (CTMS).
The Clinical Trial (CTMS) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Clinical Trial (CTMS) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Clinical Trial (CTMS) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Oracle
Medidata Solutions
PAREXEL
IBM
ERT
Bioclinica
Forte Research Systems
Veeva Systems
MasterControl
MedNet Solutions
DSG
Bio-Optronics
DATATRAK
DZS Software Solutions
ArisGlobal
Segment by Type
Enterprise CTMS
Site CTMS
Segment by Application
Pharma & Biopharmaceutical Companies
Clinical Research Organizations
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Clinical Trial (CTMS) companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Clinical Trial (CTMS) 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Enterprise CTMS
1.2.3 Site CTMS
1.3 麻豆原创 by Application
1.3.1 Global Clinical Trial (CTMS) 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharma & Biopharmaceutical Companies
1.3.3 Clinical Research Organizations
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Clinical Trial (CTMS) 麻豆原创 Perspective (2018-2029)
2.2 Clinical Trial (CTMS) Growth Trends by Region
2.2.1 Global Clinical Trial (CTMS) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Clinical Trial (CTMS) Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Clinical Trial (CTMS) Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Clinical Trial (CTMS) 麻豆原创 Dynamics
2.3.1 Clinical Trial (CTMS) Industry Trends
2.3.2 Clinical Trial (CTMS) 麻豆原创 Drivers
2.3.3 Clinical Trial (CTMS) 麻豆原创 Challenges
2.3.4 Clinical Trial (CTMS) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Clinical Trial (CTMS) Players by Revenue
3.1.1 Global Top Clinical Trial (CTMS) Players by Revenue (2018-2023)
3.1.2 Global Clinical Trial (CTMS) Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Clinical Trial (CTMS) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Clinical Trial (CTMS) Revenue
3.4 Global Clinical Trial (CTMS) 麻豆原创 Concentration Ratio
3.4.1 Global Clinical Trial (CTMS) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Clinical Trial (CTMS) Revenue in 2022
3.5 Clinical Trial (CTMS) Key Players Head office and Area Served
3.6 Key Players Clinical Trial (CTMS) Product Solution and Service
3.7 Date of Enter into Clinical Trial (CTMS) 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Trial (CTMS) Breakdown Data by Type
4.1 Global Clinical Trial (CTMS) Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Clinical Trial (CTMS) Forecasted 麻豆原创 Size by Type (2024-2029)
5 Clinical Trial (CTMS) Breakdown Data by Application
5.1 Global Clinical Trial (CTMS) Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Clinical Trial (CTMS) Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Clinical Trial (CTMS) 麻豆原创 Size (2018-2029)
6.2 North America Clinical Trial (CTMS) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Clinical Trial (CTMS) 麻豆原创 Size by Country (2018-2023)
6.4 North America Clinical Trial (CTMS) 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Clinical Trial (CTMS) 麻豆原创 Size (2018-2029)
7.2 Europe Clinical Trial (CTMS) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Clinical Trial (CTMS) 麻豆原创 Size by Country (2018-2023)
7.4 Europe Clinical Trial (CTMS) 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Clinical Trial (CTMS) 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Clinical Trial (CTMS) 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Clinical Trial (CTMS) 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Clinical Trial (CTMS) 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Clinical Trial (CTMS) 麻豆原创 Size (2018-2029)
9.2 Latin America Clinical Trial (CTMS) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Clinical Trial (CTMS) 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Clinical Trial (CTMS) 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Clinical Trial (CTMS) 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Clinical Trial (CTMS) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Clinical Trial (CTMS) 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Clinical Trial (CTMS) 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Oracle
11.1.1 Oracle Company Detail
11.1.2 Oracle Business Overview
11.1.3 Oracle Clinical Trial (CTMS) Introduction
11.1.4 Oracle Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.1.5 Oracle Recent Development
11.2 Medidata Solutions
11.2.1 Medidata Solutions Company Detail
11.2.2 Medidata Solutions Business Overview
11.2.3 Medidata Solutions Clinical Trial (CTMS) Introduction
11.2.4 Medidata Solutions Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.2.5 Medidata Solutions Recent Development
11.3 PAREXEL
11.3.1 PAREXEL Company Detail
11.3.2 PAREXEL Business Overview
11.3.3 PAREXEL Clinical Trial (CTMS) Introduction
11.3.4 PAREXEL Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.3.5 PAREXEL Recent Development
11.4 IBM
11.4.1 IBM Company Detail
11.4.2 IBM Business Overview
11.4.3 IBM Clinical Trial (CTMS) Introduction
11.4.4 IBM Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.4.5 IBM Recent Development
11.5 ERT
11.5.1 ERT Company Detail
11.5.2 ERT Business Overview
11.5.3 ERT Clinical Trial (CTMS) Introduction
11.5.4 ERT Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.5.5 ERT Recent Development
11.6 Bioclinica
11.6.1 Bioclinica Company Detail
11.6.2 Bioclinica Business Overview
11.6.3 Bioclinica Clinical Trial (CTMS) Introduction
11.6.4 Bioclinica Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.6.5 Bioclinica Recent Development
11.7 Forte Research Systems
11.7.1 Forte Research Systems Company Detail
11.7.2 Forte Research Systems Business Overview
11.7.3 Forte Research Systems Clinical Trial (CTMS) Introduction
11.7.4 Forte Research Systems Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.7.5 Forte Research Systems Recent Development
11.8 Veeva Systems
11.8.1 Veeva Systems Company Detail
11.8.2 Veeva Systems Business Overview
11.8.3 Veeva Systems Clinical Trial (CTMS) Introduction
11.8.4 Veeva Systems Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.8.5 Veeva Systems Recent Development
11.9 MasterControl
11.9.1 MasterControl Company Detail
11.9.2 MasterControl Business Overview
11.9.3 MasterControl Clinical Trial (CTMS) Introduction
11.9.4 MasterControl Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.9.5 MasterControl Recent Development
11.10 MedNet Solutions
11.10.1 MedNet Solutions Company Detail
11.10.2 MedNet Solutions Business Overview
11.10.3 MedNet Solutions Clinical Trial (CTMS) Introduction
11.10.4 MedNet Solutions Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.10.5 MedNet Solutions Recent Development
11.11 DSG
11.11.1 DSG Company Detail
11.11.2 DSG Business Overview
11.11.3 DSG Clinical Trial (CTMS) Introduction
11.11.4 DSG Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.11.5 DSG Recent Development
11.12 Bio-Optronics
11.12.1 Bio-Optronics Company Detail
11.12.2 Bio-Optronics Business Overview
11.12.3 Bio-Optronics Clinical Trial (CTMS) Introduction
11.12.4 Bio-Optronics Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.12.5 Bio-Optronics Recent Development
11.13 DATATRAK
11.13.1 DATATRAK Company Detail
11.13.2 DATATRAK Business Overview
11.13.3 DATATRAK Clinical Trial (CTMS) Introduction
11.13.4 DATATRAK Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.13.5 DATATRAK Recent Development
11.14 DZS Software Solutions
11.14.1 DZS Software Solutions Company Detail
11.14.2 DZS Software Solutions Business Overview
11.14.3 DZS Software Solutions Clinical Trial (CTMS) Introduction
11.14.4 DZS Software Solutions Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.14.5 DZS Software Solutions Recent Development
11.15 ArisGlobal
11.15.1 ArisGlobal Company Detail
11.15.2 ArisGlobal Business Overview
11.15.3 ArisGlobal Clinical Trial (CTMS) Introduction
11.15.4 ArisGlobal Revenue in Clinical Trial (CTMS) Business (2018-2023)
11.15.5 ArisGlobal Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Oracle
Medidata Solutions
PAREXEL
IBM
ERT
Bioclinica
Forte Research Systems
Veeva Systems
MasterControl
MedNet Solutions
DSG
Bio-Optronics
DATATRAK
DZS Software Solutions
ArisGlobal

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.